Belgian Society on Thrombosis and Haemostasis
The Belgian Society on Thrombosis & Haemostasis, a non-profit medical research organization, seeks to:
- Foster and advance science
relating to thrombosis, haemostasis, and vascular biology - Provide a forum
for discussion of these problems - Encourage research
in these areas - Focus the attention of scientists
of the several relevant disciplines on these matters - Foster the diffusion and exchange of ideas
through meetings and publications
Belgian Journal of Hematology
The Belgian Journal of Hematology (BJH) is the official journal of the Belgian Society on Thrombosis and Haemostasis.
BJH is the journal for training of medical specialists working in the field of Haematology in Belgium or Luxembourg in the broadest sense.
Upcoming events
13-15 September 2023
4th European Congress on Thrombosis and Haemostasisis (ECTH)
Valencia-Spain
For more information Click here
30 November-1 December 2023
30th Annual meeting BSTH
Mechelen-Belgium
For more information Click here
More interesting international meetings: www.isth.org
COVID-19 Resources
Information and updates about the COVID-19 can be found on the page COVID-19 Resources
Get involved and become a member of BSTH!
- Open to all persons interested and working in the field of thrombosis and haemostasis in Belgium, including healthcare and research
- Membership by paying yearly membership fees (deadline for the running year: November 30)
- Corporate membership available
- Clear membership benefits have been defined
- Only members are eligible for BSTH grants, organizational positions or voting at BSTH General Assembly
BSTH news
News 4/5-2023
BSTH partner of the ECTH
News 13/10/2021
TODAY IS THE WORLD THROMBOSIS DAY
KEEP YOUR EYES OPEN ON THROMBOSIS
ISTH newsletter: Click here to open
COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets
News 18/03/2021
EMA’s safety committee, PRAC, concluded its preliminary review of a signal of blood clots in people vaccinated with COVID-19 Vaccine AstraZeneca at its extraordinary meeting of 18 March 2021. The Committee confirmed that:
- the benefits of the vaccine in combating the still widespread threat of COVID-19 (which itself results in clotting problems and may be fatal) continue to outweigh the risk of side effects;
- the vaccine is not associated with an increase in the overall risk of blood clots (thromboembolic events) in those who receive it;
- there is no evidence of a problem related to specific batches of the vaccine or to particular manufacturing sites;
- however, the vaccine may be associated with very rare cases of blood clots associated with thrombocytopenia, i.e. low levels of blood platelets (elements in the blood that help it to clot) with or without bleeding, including rare cases of clots in the vessels draining blood from the brain (CVST).
ISTH Statement on AstraZeneca COVID-19 Vaccine and Thrombosis
The International Society on Thrombosis and Hemostasis (ISTH) recommends that all eligible adults continue to receive their COVID-19 vaccinations, despite the recent decisions by Austria, Denmark, Norway and Iceland to at least temporarily suspend the use of the AstraZeneca vaccine due to reports of thrombosis.
Read the statement online here
ISTH Statement on COVID-19 and Venous Thromboembolism (VTE)
BSTH contributed to this statement together with 70 other organizations around the world.
AHA/ISTH Scientific Statement:
Venous Thromboembolism Research Priorities
Venous thromboembolism is a major cause of morbidity and mortality. The impact of the US Surgeon General’s The Surgeon General’s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism in 2008 has been lower than expected given the public health impact of this disease. This scientific statement highlights future research priorities in venous thromboembolism, developed by experts and a crowdsourcing survey across 16 scientific organizations.
COVID-19
Belgian consensus documents on Anticoagulation management in COVID-19 are available now!
ISTH came forward with recommendations and practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19.
This is a living guidance document that will be updated weekly.
